Mikael Ebbo
Aix-Marseille University
Internal medicineSurgeryPathologyAntibodyRetrospective cohort studyPediatricsAdverse effectImmunologyVasculitisRetroperitoneal fibrosisDiseaseIgG4-related diseaseRituximabPopulationInnate lymphoid cellClinical trialMedicineBiologyImmune systemGastroenterology
Publications 85
#1Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 14
#2Andreu Fernández-Codina (UWO: University of Western Ontario)H-Index: 9
Last. Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 25
view all 7 authors...
INTRODUCTION Awareness of IgG4-related disease (IgG4-RD) is increasing worldwide and specialists are now familiar with most of its clinical manifestations and mimickers. IgG4-RD promptly responds to glucocorticoids and repeated courses are typically used to induce and maintain remission because the disease relapses in most patients. If left untreated it can lead to organ dysfunction, organ failure and death. Advancement in our understanding of IgG4-RD pathogenesis is leading to the identificatio...
#1Mohamed Hamidou (University of Nantes)H-Index: 47
#2Antoine Néel (University of Nantes)H-Index: 23
Last. François Rieger (CNRS: Centre national de la recherche scientifique)H-Index: 32
view all 12 authors...
BACKGROUND Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a short course of intravenous ATO in patients with active SLE. METHODS This phase IIa, open-label, dose-escalating study enrolled 11 adult SLE patients with a non-organ threatening disease, clinically active despite conventional therapy. Patients received 10 IV infusions of ATO within...
#1Alexandre Nguyen (UNICAEN: University of Caen Lower Normandy)H-Index: 1
#2Y. Repessé (UNICAEN: University of Caen Lower Normandy)H-Index: 3
Last. Achille Aouba (UNICAEN: University of Caen Lower Normandy)H-Index: 25
view all 15 authors...
The mechanisms of action of intravenous immunoglobulins (IVIg) in autoimmune diseases are not fully understood. The fixed duration of efficacy and noncumulative effects of IVIg in immune thrombocytopenia (ITP) and acquired von Willebrand disease (AVWD) suggest other mechanisms besides immunologic ones. Additionally to the peripheral destruction of platelets in ITP, their medullary hypoproduction emerged as a new paradigm with rescue of thrombopoietin receptor agonists (TPO-RA). In an ITP mouse m...
#1Marc Michel (University of Paris)H-Index: 28
#2Marco RuggeriH-Index: 41
Last. Bertrand Godeau (University of Paris)H-Index: 36
view all 11 authors...
Management of immune thrombocytopenia (ITP) during pregnancy can be challenging since treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the placenta, are not recommended during pregnancy. To better assess safety and efficacy of off-label use of Tpo-RA during pregnancy, a multicenter observational and retrospective study was set up. Results from 15 pregnant women with ITP (17 pregnancies and 18 neonates) treated with either eltrombopag (N=8) or romiplos...
5 CitationsSource
#1M. Roussotte (HCL Technologies)H-Index: 1
#2M. Gerfaud-Valentin (HCL Technologies)H-Index: 1
Last. Pascal Sève (HCL Technologies)H-Index: 38
view all 18 authors...
Introduction Approximativement 20 % des lupiques presentent une thrombopenie immunologique (TI). La TI cliniquement significative (TICS) secondaire au lupus erythemateux systemique (LES) (TICS-LES) concernerait quant a elle 5 % des patients [1] . La prise en charge de la TICS-LES ne fait pas consensus a l’ere des traitements recemment developpes pour la TI primaire. Patients et methodes Etude retrospective dans 15 services de medecine interne du Centre-Est et Sud, incluant des adultes lupiques (...
#1Etienne Crickx (University of Paris)H-Index: 9
#2Guillaume Moulis (University of Toulouse)H-Index: 19
Last. Matthieu Mahévas (University of Paris)H-Index: 23
view all 12 authors...
#1Olivier DemariaH-Index: 10
#1Olivier DemariaH-Index: 10
Last. Eric VivierH-Index: 100
view all 16 authors...
#1Julien RohmerH-Index: 3
Last. CereoH-Index: 1
view all 39 authors...
FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia (F/P+ MN-eo) is a rare disease: robust epidemiological data are lacking and reported issues are scarce, of low sample-size and limited follow-up. Imatinib mesylate (IM) is highly efficient but no predictive factor of relapse after discontinuation has yet been identified. One hundred and fifty-one patients with F/P+ MN-eo (143 males; mean age at diagnosis 49 years; mean annual incidence: 0.18 case per million population) were included in t...
2 CitationsSource
#1Romain Muller (AMU: Aix-Marseille University)H-Index: 1
#2Antoine Briantais (AMU: Aix-Marseille University)H-Index: 1
Last. Nicolas Schleinitz (AMU: Aix-Marseille University)H-Index: 36
view all 13 authors...
1 CitationsSource
#1Julien Carvelli (AMU: Aix-Marseille University)H-Index: 8
#2Olivier DemariaH-Index: 10
Last. Eric Vivier (AMU: Aix-Marseille University)H-Index: 100
view all 22 authors...
Coronavirus disease 2019 (COVID-19) is a new pandemic disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. The C5a anaphylatoxin and its receptor C5aR1 (CD88) play a key role in the initiation and maintenance of several inflammatory responses, by recruiting and activating neutrophils and monocytes in the lungs1. We provide a longitudinal analysis of immune responses, including immune cell phenotyping and assessments of the soluble factors present in the...
74 CitationsSource
Close Researchers